Analysis Tools|
Allele Symbol Allele Name Allele ID |
Tg(Myh6-cre)TG9Pjay transgene insertion TG9, Patrick Y Jay MGI:5496902 |
||||||||||||
| Summary |
2 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice exhibit shortened lifespan compared to single Tg(Myh6-cre)TG9Pjay transgenic mice
|
|
• mice exhibit accelerated progression of heart failure compared to single Tg(Myh6-cre)TG9Pjay transgenic mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• swim exercise training before cardiac function abnormalities improves lifespan, with mean age increased by about 20% and 16% in males and females, respectively
(J:119070)
• maximum life span of females and males is 11 and 13 weeks, respectively
(J:198043)
• treatment with captopril, an angiotensin converting enzyme inhibitor, prolongs survival by 1 week in females and by 2 weeks in males
(J:198043)
• treatment with metoprolol, a beta1-adrenergic receptor blocker, has a small effect on increased survival
(J:198043)
|
|
• severe pulmonary congestion in end-stage heart failure as indicated by increased lung-to-body weight ratios
|
|
• ventricular chamber dilation with a thin myocardial wall
|
|
• left ventricular dilation is present by 57 days of age and becomes more pronounced over the next 2 weeks
|
|
• mice develop severe dilated cardiomyopathy showing progressive dilation of the left ventricular end-diastolic diameter, worsening systolic function, and a trend towards thinning of the left ventricular wall
(J:198043)
• however, no myocardial fibrosis is present
(J:198043)
|
|
• systolic dysfunction is present by 57 days of age and becomes more pronounced over the next 2 weeks, with decreased fractional shortening and progressive dilation of the left ventricular end-diastolic diameter
|
|
• 2-fold increase in incidence of cardiac myocyte apoptosis at 7 weeks of age
|
|
• mice become fatigued and sedentary, and show labored breathing before death due to heart failure
|
|
• 2-fold increase in incidence of cardiac myocyte apoptosis at 7 weeks of age
|
|
• organized thrombi in the left atrium
|
|
• mice develop severe dilated cardiomyopathy showing progressive dilation of the left ventricular end-diastolic diameter, worsening systolic function, and a trend towards thinning of the left ventricular wall
(J:198043)
• however, no myocardial fibrosis is present
(J:198043)
|
|
• systolic dysfunction is present by 57 days of age and becomes more pronounced over the next 2 weeks, with decreased fractional shortening and progressive dilation of the left ventricular end-diastolic diameter
|
|
• 2-fold increase in incidence of cardiac myocyte apoptosis at 7 weeks of age
|
|
• severe pulmonary congestion in end-stage heart failure as indicated by increased lung-to-body weight ratios
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| congestive heart failure | DOID:6000 | J:198043 | ||
| dilated cardiomyopathy | DOID:12930 |
OMIM:PS115200 |
J:119070 | |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 09/30/2025 MGI 6.24 |
|
|
|
||
